Last reviewed · How we verify

NCT03466255: VIBE

Early Detection of Cardiovascular Disease

Completed Last updated 9 June 2022
What this trial tests

trial testing Ultrasound in Atheroma in 610 participants. Completed in 11 January 2022.

Timeline
6 December 2016
Primary endpoint
8 June 2021
11 January 2022

Quick facts

Lead sponsorDr. Amer Johri
StatusCompleted
Study typeOBSERVATIONAL
Enrollment610
Start date6 December 2016
Primary completion8 June 2021
Estimated completion11 January 2022
Sites1 location across Canada

Drugs / interventions tested

Conditions studied

Sponsor

Dr. Amer Johri

Who can join

18 and older, any sex, with Atheroma or Cardiac Disease. Patients with the condition only — healthy volunteers not accepted.

Sponsor's own description

The investigators plan to evaluate the correlation between carotid plaque enhancement on Contrast-enhanced ultrasound (CEUS), significant coronary artery disease (CAD), and cardiovascular (CV) outcomes in a systematic manner. The investigators hypothesize that increased levels of CEUS-detected vulnerable carotid plaque will be predictive of CV risk determined by angiography and future cardiovascular events.

Publications & conference data

No peer-reviewed publications indexed yet for this trial. Completed trials usually publish results within 12-18 months.

Verify or expand the search:

Other trials of Ultrasound

Trials testing the same drug.

Other recruiting trials for Atheroma

Currently open trials in the same condition.

Other Dr. Amer Johri trials

Trials by the same sponsor.

Verify against primary sources

Data sources for this page

Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT03466255.

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing